ArticleMedicine2026
Research on the mechanism of Duhuo in treating intervertebral disc degeneration based on bioinformatics and network pharmacology.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Low back pain caused by intervertebral disc degeneration (IVDD), a common orthopedic disease in middle-aged and elderly populations, burdens patients' quality of life and work capacity. IVDD is closely associated with nucleus pulposus cell apoptosis and autophagy, mediated by BCL2, CASP3, CASP8, and CASP9. Although Duhuo alleviates inflammation and delays IVDD, its molecular mechanism remains unclear. We used bioinformatics to identify IVDD-related apoptotic/autophagic pathways and Duhuo's therapeutic mechanisms via network pharmacology. Bioinformatic analysis showed high expression of NLRP3, IL6, AKT1, and MMP9 in IVDD patients, with key cellular processes including senescence, apoptosis, autophagy, and ferroptosis, critical signaling pathways (HIF-1, FoxO, and PI3K-Akt), and main immune cells (T cells and Th17 cells). Network pharmacology identified Duhuo's main active components (ammidin, isoimperatorin, β-sitosterol, O-acetylcolumbianetin, and angelol D) and 23 potential targets, among which BCL2, CASP3, CASP8, CASP9, ERR1, and PTGS1 are crucial. Enrichment analysis indicated Duhuo prevents IVDD by regulating apoptosis, autophagy, HIF-1, and PI3K-Akt pathways, and molecular docking confirmed β-sitosterol effectively binds key targets. This study identifies IVDD's molecular basis and establishes a mechanism for targeted regulation of nucleus pulposus cell apoptosis/autophagy to prevent IVDD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.